Lewis Katz School of Medicine at Temple University research shows Pison’s Neural Biosensor can potentially enable remote monitoring, early detection and intervention for neurological diseases
Pison have announced the results of recent clinical trial conducted by researchers at the Lewis Katz School of Medicine at Temple University’s MDA/ALS Center of Hope, in the US. The trials concluded that Pison’s Neural Biosensor hardware and electroneurography (ENG) technology was able to distinguish patients with amyotrophic lateral sclerosis (ALS) from a healthy population and detect changes in surface electromyography (sEMG) in ALS patients which reflects motor neuron changes and is correlated with functional changes. These results demonstrate that Pison’s technology has the potential to become a digital biomarker to detect neurological diseases, monitor progression, and inform treatment.
In addition, Pison’s ongoing efforts to embed their technology into wearable devices, such as smart watches, opens the door for continuous monitoring of patients and even pre-symptomatic populations.
The study, funded by The ALS Association and the National Science Foundation and led by Dr. Terry Heiman-Patterson, Professor of Neurology and Director of the MDA/ALS Center of Hope at the Lewis Katz School of Medicine at Temple University, used Pison’s technology to classify electromyography activity and fasciculations in patients in the early stages of ALS. The study found that Pison’s technology could distinguish between patients diagnosed with ALS and a healthy population.
More at PISON Technology
New and better ways to diagnose and monitor people with ALS are urgently needed. We are proud to have supported the initial testing of this promising new technology. We look forward to seeing the results of future studies to confirm and validate these findings with larger groups of participants.
Dr. Kuldip Dave, Senior Vice President of Research at The ALS Association.
